The present study reports an engineered poly-l-lactide-co-glycolic acid (PLGA)–casein polymer–protein hybrid nanocarrier 190 ± 12 nm in size entrapping a combination of chemically distinct (hydrophobic/hydrophilic) model drugs. A simple emulsion–precipitation route was adopted to prepare nearly monodispersed nanoparticles with distinct core/shell morphology entrapping paclitaxel (Ptx) in the core and epigallocatechin gallate (EGCG) in the shell, with the intention of providing a sequential and sustained release of these drugs. The idea was that an early release of EGCG would substantially increase the sensitivity of Ptx to cancer, thereby providing improved
EGCG from Chengdu Biopurify Phytochemicals Ltd., PR China.
